GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (LTS:0Q4U) » Definitions » COGS-to-Revenue

Novonesis (Novozymes) B (LTS:0Q4U) COGS-to-Revenue : 0.45 (As of Mar. 2025)


View and export this data going back to 2006. Start your Free Trial

What is Novonesis (Novozymes) B COGS-to-Revenue?

Novonesis (Novozymes) B's Cost of Goods Sold for the three months ended in Mar. 2025 was kr3,605 Mil. Its Revenue for the three months ended in Mar. 2025 was kr8,037 Mil.

Novonesis (Novozymes) B's COGS to Revenue for the three months ended in Mar. 2025 was 0.45.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Novonesis (Novozymes) B's Gross Margin % for the three months ended in Mar. 2025 was 55.15%.

Novonesis (Novozymes) B COGS-to-Revenue Historical Data

The historical data trend for Novonesis (Novozymes) B's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B COGS-to-Revenue Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.42 0.45 0.46 0.53

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.57 0.59 0.48 0.45

Novonesis (Novozymes) B COGS-to-Revenue Calculation

Novonesis (Novozymes) B's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=15094.377 / 28589.079
=0.53

Novonesis (Novozymes) B's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3604.791 / 8037.498
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B  (LTS:0Q4U) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Novonesis (Novozymes) B's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 3604.791 / 8037.498
=55.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Novonesis (Novozymes) B COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (LTS:0Q4U) » Definitions » COGS-to-Revenue
Comparable Companies
OCSE:SPG OCSE:FLUG B OCSE:HOVE LIN XPAR:AI SHW ECL APD ISX:TPIA XSWX:GIVN XSWX:SIKA XAMS:DSFIR DD BOM:500820 PPG SHSE:600309 ADX:BOROUGE IFF NSE:PIDILITIND LYB
Traded in Other Exchanges
NVZMY:USA NVZMF:USA NSISBc:UK NSIS B:Denmark NZM2:Germany NZYM:Austria
Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Website
https://www.novozymes.com
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines